Regulators approve expanded emergency use of Eli Lilly’s COVID-19 treatment
INDIANAPOLIS — The U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization for Eli Lilly’s anti-inflammatory drug baricitinib used to treat COVID-19.FDA action provides physicians additional treatment regimen options for baricitinib to continue to meet the urgent medical needs posed by this pandemic.